In today’s briefing:
- Bangkok Dusit Medical (BDMS TB): Stable 2024 Performance as International Patients Drive Growth
- WuXi AppTec (2359 HK): In-Line 2024 Performance; Announces Dividend and A Share Buyback Plan
- UnitedHealth: The Expansion of Optum’s Integrated Healthcare Services Might Just Be The Single Most Important Catalyst For Them Today!
- Hinge Health (HNGE): Peeking at the Prospectus of the Next Software/Healthcare IPO
- Marpai Inc – MS Microcaps Conference: Company Spotlights & Key Takeaways
- Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism!
- NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
- Option Care Health: Is Its Expansion of Advanced Practitioner Model The Right Move to Capture Significant Market Share?
- QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
- REVB: Study Shows Positive Results
Bangkok Dusit Medical (BDMS TB): Stable 2024 Performance as International Patients Drive Growth
- Bangkok Dusit Medical Services (BDMS TB) posted 7% rise in revenue from hospital operations in 2024 as both International and Thai patients revenue reported growth of 11% and 5%, respectively.
- EBITDA grew 7% YoY to THB26.6B on higher revenues and better cost management while net profit also rose to THB16B on lower interest cost.
- COEs, focusing trauma, heart, orthopedics, cancer, and neuro contributed 57% of hospital revenue, while their contribution to EBITDA was at 60% in 2024.
WuXi AppTec (2359 HK): In-Line 2024 Performance; Announces Dividend and A Share Buyback Plan
- WuXi AppTec (2359 HK) has reported 2024 result, with revenue reaching RMB39.2M, in-line with guidance of RMB38.3–40.5B. Excluding Covid-19 commercial project, 2024 revenue represents 5% YoY growth.
- The company has announced a cash dividend of RMB9.8 and a special dividend of RMB3.5 for every 10 shares. Wuxi AppTech has also proposed RMB 1B buyback plan (for A-shares).
- Based on the current backlog, Wuxi AppTech expects continuing operations revenue to resume double-digit growth of 10–15% YoY in 2025, targeting to deliver a total revenue of RMB41.5–43.0B.
UnitedHealth: The Expansion of Optum’s Integrated Healthcare Services Might Just Be The Single Most Important Catalyst For Them Today!
- UnitedHealth Group’s fourth quarter and full year 2024 results were characterized by resilience and strong operational execution despite significant challenges.
- Revenues exceeded $400 billion, with an adjusted earnings per share of $27.66, aligning with the company’s projections.
- Notably, the medical care ratio was 150 basis points above the initial outlook, mainly due to a mix change of the people served, a more rapid acceleration in certain high-cost medication prescriptions, and coding intensity shifts in hospitals.
Hinge Health (HNGE): Peeking at the Prospectus of the Next Software/Healthcare IPO
- They have designed their platform to address a broad spectrum of Musculoskeletal system (MSK) care—from acute injury, to chronic pain, to post-surgical rehabilitation.
- As of December 31, 2024, they had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023.
- Their revenue was $390.4 million and $292.7 million for the years ended December 31, 2024 and 2023, respectively, representing a year-over-year growth rate of 33%.
Marpai Inc – MS Microcaps Conference: Company Spotlights & Key Takeaways
- We recently teamed up with MS Microcaps to publish Company Spotlight reports on the companies presenting at its conference earlier this month.
- The reports aim to serve as an introduction to each company and provide a basic investment thesis.
- For access to full versions of all interviews please visit either mscliffnotes.substack.com or geoinvesting.com/free-trial/.
Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism!
- Natera Inc. presented its fourth quarter 2024 financial results, signaling a robust period for the company as they continue to expand and enhance their operations.
- The company’s revenues for the quarter reached $476 million, marking a substantial 53% increase year-on-year and exceeding their January pre-announcement by $4 million.
- This robust revenue growth is attributed to an increase in test volumes across their product lines, with a particular highlight on the 60% clinical volume growth of Signatera compared to the fourth quarter of 2023.
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
- NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.
- The technology involved also has the potential to more efficiently get other treatments to the needed area.
- The company announced that a preclinical study demonstrated that ExoPTEN treatment led to motor function recovery and improvements in blood flow-both positive signs for an IND submission.
Option Care Health: Is Its Expansion of Advanced Practitioner Model The Right Move to Capture Significant Market Share?
- Option Care Health recently reported its financial performance for the fourth quarter and full year of 2024.
- During the call, the executives outlined several aspects of their performance, strategic initiatives, and future outlook.
- Key takeaways include a robust revenue growth rate of approximately 19.7% year-over-year in the fourth quarter and an overall satisfactory management of operational challenges such as supply chain issues.
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
- In Dec.
- 2024, Quoin received FDA clearance to initiate a new investigator led whole-body clinical study for QRX003, which will evaluate the safety and efficacy of twice-daily application of QRX003 to more than 80% of the body surface area in NS patients, an application dosage QNRX anticipates in real-world usage if QRX003 obtains regulatory approval.
- This represents the most extensive clinical application of QRX003 thus far.
REVB: Study Shows Positive Results
- Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system.
- The company announced that a study on its flagship Gemini treatment showed the drug reduces inflammation in human blood cells.
- These results hold great promise for the treatment of conditions such as CKD (chronic kidney disease).
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries